Related Experiment Video
Updated: Jul 6, 2026
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Strategies to examine new compounds for intraperitoneal use in ovarian cancer
1The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. mmarkman@mdanderson.org
Abstract:
The results of three large well-designed randomized trials demonstrating the favorable impact of primary cisplatin-based chemotherapy on survival in small-volume residual advanced ovarian cancer has stimulated considerable interest in exploration of this route of drug delivery for other antineoplastic agents. A number of relevant properties of both the drugs and the peritoneal cavity need to be considered in preclinical evaluation such that future clinical development will focus on strategies that have a realistic potential for being safe and effective when they enter the clinical arena.
Insights
Primary cisplatin chemotherapy improves survival in advanced ovarian cancer. This success prompts further research into using the peritoneal cavity for delivering other anti-cancer drugs, requiring careful preclinical evaluation for safety and effectiveness.
Area of Science:
- Oncology
- Pharmacology
- Drug Delivery Systems
Background:
- Advanced ovarian cancer treatment has seen survival improvements with primary cisplatin-based chemotherapy.
- The success of this approach has generated interest in alternative drug delivery routes.
Purpose of the Study:
- To explore the potential of the peritoneal cavity for delivering other antineoplastic agents.
- To identify key considerations for preclinical evaluation of novel drug delivery strategies.
Main Methods:
- Review of existing randomized trials on cisplatin-based chemotherapy for ovarian cancer.
- Analysis of drug and peritoneal cavity properties relevant to drug delivery.
- Consideration of factors for successful preclinical to clinical translation.
Main Results:
- Cisplatin-based chemotherapy demonstrates a favorable impact on survival in specific ovarian cancer cases.
- The peritoneal route offers a promising avenue for novel antineoplastic agent delivery.
Conclusions:
- Further investigation into peritoneal drug delivery for ovarian cancer is warranted.
- Thorough preclinical evaluation is crucial for developing safe and effective strategies for clinical application.
